Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Akero Therapeutics Reports First Patient Randomized For Dosing In Phase 2b Study Of Efruxifermin In F2/F3 NASH Patients


Benzinga | Mar 23, 2021 08:12AM EDT

Akero Therapeutics Reports First Patient Randomized For Dosing In Phase 2b Study Of Efruxifermin In F2/F3 NASH Patients






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC